Biopharma Service Providers Address a Full Plate of Challenges
Contract service providers debate the pros and cons of consolidation, accelerated drug approvals, regulatory issues, and the impact of new therapies.
Contract service providers debate the pros and cons of consolidation, accelerated drug approvals, regulatory issues, and the impact of new therapies.
Participants in this discussion included: Don Paul Kovarcik, technical marketing specialist, Ajinomoto Althea; Robert H. DeWit, president of MPI Research; John Allinson, head of biomarker strategy, drug development services at LGC; Michael Lehmann, president, global sales and marketing, Patheon; Brian Hampson, vice-president, global manufacturing sciences and technology, PCT, a Caladrius Company; Fiona Greer, global director, BioPharma Services Development–Life Sciences, SGS; and Peter Soelk, managing director, Vetter Pharma International.
Download the
BioPharm International 2016 Outsourcing Resources eBook.
Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck
May 28th 2025Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
